E. Ohman J or Asset Management AB Purchases 2,150 Shares of Zoetis Inc. (NYSE:ZTS)

E. Ohman J or Asset Management AB boosted its position in shares of Zoetis Inc. (NYSE:ZTS) by 11.6% in the 4th quarter, according to its most recent filing with the Securities & Exchange Commission. The fund owned 20,750 shares of the company’s stock after purchasing an additional 2,150 shares during the period. E. Ohman J or Asset Management AB’s holdings in Zoetis were worth $3,381,000 at the end of the most recent quarter.

Other institutional investors and hedge funds have also recently added to or reduced their stakes in the company. Mather Group LLC. boosted its holdings in shares of Zoetis by 4.6% in the 4th quarter. Mather Group LLC. now owns 3,398 shares of the company’s stock worth $554,000 after acquiring an additional 148 shares in the last quarter. Rockline Wealth Management LLC boosted its stake in Zoetis by 4.5% in the fourth quarter. Rockline Wealth Management LLC now owns 5,823 shares of the company’s stock worth $949,000 after purchasing an additional 252 shares in the last quarter. Calamos Wealth Management LLC grew its holdings in shares of Zoetis by 21.0% during the fourth quarter. Calamos Wealth Management LLC now owns 84,030 shares of the company’s stock worth $13,691,000 after purchasing an additional 14,568 shares during the last quarter. Calamos Advisors LLC increased its stake in shares of Zoetis by 15.0% in the fourth quarter. Calamos Advisors LLC now owns 210,885 shares of the company’s stock valued at $34,359,000 after buying an additional 27,579 shares in the last quarter. Finally, Childress Capital Advisors LLC raised its holdings in shares of Zoetis by 30.6% in the fourth quarter. Childress Capital Advisors LLC now owns 1,599 shares of the company’s stock valued at $261,000 after buying an additional 375 shares during the last quarter. 92.80% of the stock is currently owned by institutional investors and hedge funds.

Zoetis Trading Up 0.6 %

Zoetis stock opened at $171.93 on Tuesday. Zoetis Inc. has a one year low of $144.80 and a one year high of $200.53. The company has a debt-to-equity ratio of 1.26, a current ratio of 3.69 and a quick ratio of 2.27. The firm has a 50-day moving average of $169.62 and a 200-day moving average of $179.44. The company has a market cap of $77.57 billion, a price-to-earnings ratio of 32.32, a P/E/G ratio of 2.72 and a beta of 0.90.

Zoetis (NYSE:ZTS) last released its quarterly earnings data on Monday, November 4th. The company reported $1.58 earnings per share (EPS) for the quarter, beating the consensus estimate of $1.46 by $0.12. Zoetis had a return on equity of 51.98% and a net margin of 26.55%. The firm had revenue of $2.40 billion for the quarter, compared to analyst estimates of $2.29 billion. During the same quarter in the prior year, the company earned $1.36 earnings per share. The business’s revenue for the quarter was up 11.6% compared to the same quarter last year. On average, equities analysts expect that Zoetis Inc. will post 5.9 earnings per share for the current fiscal year.

Zoetis Increases Dividend

The company also recently announced a quarterly dividend, which will be paid on Tuesday, March 4th. Stockholders of record on Tuesday, January 21st will be given a $0.50 dividend. This is an increase from Zoetis’s previous quarterly dividend of $0.43. The ex-dividend date of this dividend is Tuesday, January 21st. This represents a $2.00 annualized dividend and a dividend yield of 1.16%. Zoetis’s dividend payout ratio is presently 37.59%.

Analyst Upgrades and Downgrades

A number of equities research analysts have commented on ZTS shares. JPMorgan Chase & Co. increased their price objective on shares of Zoetis from $225.00 to $230.00 and gave the stock an “overweight” rating in a report on Friday, October 11th. UBS Group started coverage on Zoetis in a report on Monday, December 9th. They set a “neutral” rating and a $196.00 price objective for the company. Leerink Partnrs raised Zoetis to a “strong-buy” rating in a research note on Monday, December 2nd. Leerink Partners began coverage on shares of Zoetis in a report on Monday, December 2nd. They issued an “outperform” rating and a $215.00 target price on the stock. Finally, Morgan Stanley lowered their price target on Zoetis from $248.00 to $243.00 and set an “overweight” rating for the company in a report on Wednesday, January 29th. One investment analyst has rated the stock with a hold rating, ten have issued a buy rating and two have assigned a strong buy rating to the company’s stock. According to MarketBeat.com, the stock has an average rating of “Buy” and an average price target of $215.00.

About Zoetis

Zoetis Inc engages in the discovery, development, manufacture, and commercialization of animal health medicines, vaccines, and diagnostic products and services in the United States and internationally. The company commercializes products primarily across species, including livestock, such as cattle, swine, poultry, fish, and sheep and others; and companion animals comprising dogs, cats, and horses.